Last updated August 1, 2026
Reviewed by AstronovAI Editorial Team

Iris.ai vs Convexia

Compare positioning, pricing, scores, trial status, strengths, limitations, and best-fit use cases before choosing the right AI tool.

View comparison table Read takeaway

Iris.ai

57 Score 0.0 Rating Paid Pricing

Iris.ai is an enterprise AI platform for building tailored agentic workflows over scientific, technical, and regulated-domain knowledg…

C

Convexia

58 Score 0.0 Rating Freemium Pricing

AI agents for discovering and evaluating overlooked drug assets

Best decision mode No single winner
Score signal 57 vs 58 close score signal
Pricing models Paid vs Freemium
Comparison type Similar category
Best reasons to choose

Iris.ai

  • Strong fit for research-heavy organizations
  • Domain adaptation focus
  • Enterprise and regulated-workflow positioning
Best reasons to choose

Convexia

  • Combines sourcing, science, commercial, and operational analysis
  • Uses modular agents instead of one general model
  • Includes repeated human expert review
Decision guidance

Who should choose each tool?

Use this section as a fast buyer-fit shortcut before reading the full comparison table.

Choose Iris.ai if...

You need support for Research teams and Regulated enterprises. Its listed pricing model is Paid, and its main profile use is Enterprise AI knowledge workflows, research discovery, scientific literature analysis, document intelligence, agentic workflows, knowledge extraction….

Choose Convexia if...

You need support for Biotech and pharma. Its listed pricing model is Freemium, and its main profile use is Convexia scans academic, biotech, pharma, and intellectual-property sources for overlooked assets. It evaluates biology, binding, ADME, toxicity, imm….

Side-by-side profile data

Comparison table

Compare the most important decision fields without opening multiple tabs.

Pricing
Paid
Freemium
Free trial
Yes
Yes
Rating
0.0
0.0
AI score
57
58
Best fit
Research teams, Regulated enterprises, and R&D organizations
Biotech, pharma, and investment teams screening overlooked drug assets
Use case
Enterprise AI knowledge workflows, research discovery, scientific literature analysis, document intelligence, agentic workflows, knowledge extraction, and domain-adapted AI.
Convexia scans academic, biotech, pharma, and intellectual-property sources for overlooked assets. It evaluates biology, binding, ADME, toxicity, immunogenicity, market opportunity, operational risk, and historical probability of success before expert review and go or no-go decisions.
Pros
  • Strong fit for research-heavy organizations
  • Domain adaptation focus
  • Enterprise and regulated-workflow positioning
  • Useful for knowledge extraction
  • Combines sourcing, science, commercial, and operational analysis
  • Uses modular agents instead of one general model
  • Includes repeated human expert review
  • Offers a public entry point for trying agents
Cons
  • Public pricing is not transparent
  • Requires enterprise setup
  • Not focused on casual consumer research
  • Model outputs still require scientific validation
  • Full platform and pilot terms are not fully public
  • Computational diligence cannot replace wet-lab and clinical evidence

Iris.ai vs Convexia Comparison

This page compares Iris.ai and Convexia using verified profile fields from AstronovAI, including use case, pricing model, trial status, strengths, limitations, ratings, and score signals.

Both tools share a similar category context, so the comparison focuses on practical differences in positioning, feature fit, and adoption criteria.

Comparison Methodology

AstronovAI compares tools using verified profile fields such as category, primary use case, pricing model, trial status, ratings, pros, cons, and editorial review status.

Pricing

We show the listed pricing model and avoid treating unknown fields as confirmed offers.

Use Case Fit

We compare the main use case and target context of each tool before assigning any recommendation.

Profile Quality

Tools must pass content verification checks before they appear in public comparisons.

Score Signal

Scores are treated as one signal, not as a replacement for feature and use-case review.

Editorial takeaway

Which tool is the better fit?

No universal winner — choose by use case

The score signals are close or the tools serve different workflows, so this comparison is designed to match each product to the right job instead of forcing a single winner.

Iris.ai Research teams, Regulated enterprises, and R&D organizations
Convexia Biotech, pharma, and and investment teams screening overlooked drug assets

Review pricing, trial status, use cases, strengths, limitations, and profile details before choosing, especially when the tools serve different workflows.

Answers

Frequently Asked Questions

Should I choose Iris.ai or Convexia؟

Choose based on your workflow:

  • Iris.ai: Research teams, Regulated enterprises, and R&D organizations
  • Convexia: Biotech, pharma, and and investment teams screening overlooked drug assets
What separates these tools from each other?

The main difference is positioning: each tool is evaluated against its primary use case, pricing model, trial status, ratings, strengths, and limitations.

  • Iris.ai: Research teams and Regulated enterprises
  • Convexia: Biotech and pharma
Which profile should I review first?

Start with the tool whose primary use case matches your immediate goal, then check limitations and pricing before signup or procurement.

Are free plans or trials guaranteed?

No. Trial and plan information can change, so the comparison table uses the latest verified profile fields available in AstronovAI and should be checked against the vendor page before purchase.

Continue exploring

Build another AI tool comparison

Choose 2 or 3 tools and compare pricing, fit, use cases, strengths, and limitations side by side.

Open compare builder